0
0
A widely prescribed medication originally developed for type 2 diabetes and weight management may hold new promise for addressing one of the most persistent public health challenges in the world: alcohol use disorder (AUD).
According to a landmark Phase 2 clinical trial published in The Lancet, adults receiving semaglutide alongside standard therapy experienced significantly greater reductions in heavy drinking days and alcohol cravings compared to those who received a placebo. The findings, supported by earlier clinical research, suggest that GLP-1 receptor agonists—the class of drugs behind medications like Ozempic and Wegovy—may influence the neural circuitry involved in addiction and reward. While experts stress that larger Phase 3 trials are required before prescribing habits change, the research marks a potential turning point in expanding the limited pharmacological options available for alcohol addiction.
A New Frontier in Addiction Research
The Phase 2 randomized, double-blind, placebo-controlled trial enrolled 108 treatment-seeking adults diagnosed with moderate-to-severe AUD and comorbid obesity in Copenhagen, Denmark. Over a 26-week intervention period, all participants received standard cognitive behavioral therapy (CBT) and were randomly assigned to receive either once-weekly subcutaneous semaglutide (2.4 mg) or an inactive placebo.
By the end of the trial, participants in the semaglutide group demonstrated a 41.1 percentage point reduction in heavy drinking days relative to their baseline. In contrast, those in the placebo group reduced their heavy drinking days by 26.4 percentage points—yielding an estimated net treatment difference of 13.7 percentage points in favor of semaglutide.
Beyond reducing alcohol intake, the trial tracked improvements across several secondary physical health markers. The most common adverse effects were mild to moderate gastrointestinal issues, such as nausea and constipation, consistent with semaglutide’s known safety profile.
These findings build upon a smaller 2025 Phase 2 trial published in JAMA Psychiatry, which evaluated 48 adults with AUD over nine weeks. That study similarly reported reductions in alcohol cravings, total drinks consumed per drinking day, and overall heavy drinking episodes, pointing toward a possible “class effect” of GLP-1 medicines on reward-seeking behavior.
How Diabetes Medications Target Alcohol Cravings
Semaglutide works primarily by mimicking the action of glucagon-like peptide-1 (GLP-1), a natural gut hormone that regulates blood sugar levels, slows gastric emptying, and signals fullness to the brain. However, GLP-1 receptors are not confined to the digestive system; they are also present in key reward areas of the central nervous system, including the mesolimbic dopamine pathway.
When an individual consumes alcohol or palatable food, the brain releases dopamine, reinforcing the desire to repeat the behavior. Researchers believe GLP-1 receptor agonists dampen this neurochemical reward signal, effectively decreasing the urge to consume alcohol in the same way they reduce appetite for food.
This neurobiological connection gained widespread attention following real-world observational studies. Analysis of large health databases revealed that patients taking GLP-1 medications for diabetes or obesity consistently had lower rates of both new-onset and recurrent alcohol use disorder compared to those taking other treatments. The new Phase 2 trials provide critical prospective evidence directly comparing the drug against a placebo in controlled clinical settings.
The Public Health Need for Better AUD Therapies
Globally, alcohol use disorder accounts for approximately 5% of all deaths annually, contributing significantly to liver disease, cardiovascular illness, injuries, and mental health crisis. Despite the severe societal burden, existing Food and Drug Administration (FDA)-approved medications for AUD—such as naltrexone and acamprosate—remain underutilized due to variable patient response, side effect profiles, and limited awareness among primary care clinicians.
Medical experts highlight that semaglutide could address an important gap in patient care by offering an effective harm-reduction tool.
“Many patients are not necessarily looking for complete, permanent abstinence—they want to reduce heavy drinking episodes that impact their daily lives, relationships, and physical health,” explained Dr. Joseph Schacht, PhD, Associate Professor at the University of Colorado Anschutz School of Medicine, who was not involved in The Lancet study. “Even modest reductions in heavy drinking lower the long-term risk of liver injury, cardiovascular events, and social harm.”
Dr. Schacht also noted the practical advantages of exploring oral formulations of GLP-1 drugs alongside injectable options. “An oral medication that can be integrated smoothly into routine primary care settings lowers barriers to treatment. It meets patients where they are without the friction sometimes associated with specialized addiction clinics or weekly injections.”
Important Limitations and Counterarguments
While the data has energized researchers, clinicians warn against over-interpreting Phase 2 results.
Several critical study limitations remain:
-
Target Population Constraints: The Lancet trial enrolled participants who had both AUD and comorbid obesity. As a result, researchers cannot yet conclude whether the same anti-drinking benefits occur in individuals of normal body weight.
-
Confounding Therapy: Because every participant in the trial received cognitive behavioral therapy, semaglutide was tested as an adjunctive (add-on) treatment. It remains unknown how effective the medication would be without concurrent psychological support.
-
Sample Sizes: While the 2026 Copenhagen study expanded on the 48-patient 2025 trial, both studies represent Phase 2 research. Phase 3 trials involving thousands of diverse participants across multiple clinical centers are essential to establish definitive efficacy, long-term safety, and optimal dosing strategies.
-
Gastrointestinal Tolerability: GI side effects were more frequent in the semaglutide arm. For some individuals, nausea or stomach discomfort could affect adherence to treatment over extended periods.
Furthermore, medical authorities strongly caution against the off-label use of semaglutide solely for alcohol reduction outside of clinical trials. The drug is currently FDA-approved for type 2 diabetes, chronic weight management, and specific cardiovascular risk reductions—not for substance use disorders.
What This Means for Patients Today
For individuals currently managing alcohol use disorder or attempting to reduce heavy drinking, the emergence of GLP-1 research offers a promising outlook for future medical options, but clinical practice guidelines remain unchanged for now.
Healthcare providers emphasize that patients should not seek off-label semaglutide prescriptions or stop existing evidence-based treatments without medical supervision. Established therapies, including counseling, behavioral support groups, and currently approved AUD medications, remain the standard of care.
However, for patients who already meet the medical criteria for semaglutide (such as those managing both type 2 diabetes or clinical obesity alongside heavy alcohol use), these findings suggest a potential dual benefit that patients can discuss openly with their prescribing physicians.
As large-scale Phase 3 trials move forward, medical researchers remain cautiously optimistic that GLP-1 receptor agonists may eventually expand the toolkit for addiction medicine, offering new hope to millions affected by alcohol-related harm.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://www.earth.com/news/oral-semaglutide-heavy-drinking/
